Astellas Pharma Gmbh

Cytokinetics, Inc.

Ippei Sato

Masanori Miura

Bradley Paul Morgan

Hiroaki Tanaka

Pu-Ping Lu

Fady Malik

Luke W Ashcraft

Takashi Kamikubo

Scott E Collibee

Jeffrey Warrington

Tomoyuki Saito

Susumu Yamaki

Yuji Matsushima

Yasuhiro Shiina

Marc Andrew Garard

Kayoko Mihara

Hiroshi Kiyohara

Munemichi Ohe

Shunichiro Hachiya

Daisuke Kaga

Yoh Terada

Yoshimasa Imamura

Kazuhiro Terai

Koji Kato

Hiroyuki Moritomo

Makoto Takeuchi

Hiroshi Shibata

Noriyuki Kawano

Hiroyuki Koshio

Yuji Koga

Tsubasa Watanabe

Issei Tsukamoto

Kazuhiko Ohne

Takao Okuda

Kyoichi Maeno

Yoshinori Okamoto

Susumu Watanuki

Akio Kakefuda

Ryutaro Wakayama

Kenichiro Imamura

Ryo Naito

Takeshi Hanazawa

Eisuke Nozawa

Masanao Sanagi

Maiko Iida

Susumu Igarashi

Hiroyuki Kanoh

Masato Kobori

Mai Isomura

Scott Emile Collibee

Jeffrey Michael Warrington

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Tetrahydroisoquinoline derivatives

An excellent drug for treating or preventing cardiovascular diseases, based on cGMP production enhancing action due to soluble guanylate cyclase activating action, is provided. It was found that imidazopyridine compounds having a carbamoyl group at the 3-position and a substituent bonded at the 8-position via an oxygen atom in an imidazo[1,2-a]pyridine skeleton exhibits a cGMP production enhancing action by a potent soluble guanylate cyclase activating action, and is useful as a drug for treating or preventing various soluble guanylate cyclase-related cardiovascular diseases, thereby completing the present invention.

Imidazopyridine compounds

The purpose is to provide a compound which has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. A tetrahydrobenzothiophene compound of the following formula (I) has NPT-IIb inhibitory action and can be used as an agent for treating and/or preventing hyperphosphatemia: 

Tetrahydrobenzothiophene compound

[Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. [Means for Solution] The present inventors conducted their studies on a compound that has an NPT-IIb inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. As a result, they created an aminoalkyl-substituted N-thienylbenzamide derivative which has NPT-IIb inhibitory action, thereby completing the present invention. The aminoalkyl-substituted N-thienylbenzamide derivative of the present invention has an NPT-IIb inhibitory action and can be used as an agent for preventing and/or treating hyperphosphatemia.

Aminoalkyl-substituted N-thienylbenzamide derivative

As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can serve as an excellent prophylactic or therapeutic agent against a metabolic bone disease, whereby establishing the present invention. Thus, the present invention provides a 3,6-disubstituted 1,2,4-triazolo[4,3-b]pyridazine compound or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition comprising such a compound and a pharmaceutically acceptable carrier, especially a bone-forming agent.

Nitrogen-containing heterocyclic compound

To provide a compound having a superior arginine vasopressin antagonism. A novel 1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivative or a pharmaceutically acceptable salt thereof.

1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof

Growing community of inventors

Tokyo, Japan

Ippei Sato